Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy

Cancer Investigation

Volumn 35, Issue 7, 2017, Pages 443-455

  Bamias, Giorgos ^a   Delladetsima, Ioanna ^a   Perdiki, Marina ^a   Siakavellas, Spyros I ^a   Goukos, Dimitrios ^a   Papatheodoridis, George V ^a   Daikos, George L ^a   Gogas, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colitis; Immunology immunobiology; Ipilimumab; Late effects of therapy; Monoclonal antibodies

Indexed keywords

BUDESONIDE; CORTICOSTEROID; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; IPILIMUMAB; MESSENGER RNA; STEROID; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; AUTACOID; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IFNG PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; ENTEROCOLITIS; FEMALE; FEVER; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MALE; METASTATIC MELANOMA; OBSERVATIONAL STUDY; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SIGMOIDOSCOPY; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICALLY INDUCED; COLITIS; COLON; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TH1 CELL; TH17 CELL; TIME FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; COLITIS; COLON; COLONOSCOPY; CTLA-4 ANTIGEN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-17; INTESTINAL MUCOSA; MALE; MELANOMA; MIDDLE AGED; PLASMA CELLS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TH1 CELLS; TH17 CELLS; TIME FACTORS;

EID: 85019674147     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357907.2017.1324032     Document Type: Article

References (31)

1. Hwu P. Treating cancer by targeting the immune system. N Engl J Med 2010;363:779–781.
2. Marquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, Gonzalez-Cao M, et al. Immune checkpoint inhibitors:therapeutic advances in melanoma. Ann Transl Med 2015;3:267.
3. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445–3455.
4. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227–242.
5. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015;125:3377–3383.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
7. Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, et al. Treatment algorithms in stage IV melanoma. Am J Ther 2015;22:61–67.
8. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies:systematic review and meta-analysis. BMC Med 2015;13:211.
9. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors:a meta-analysis. Immunotherapy 2015;7:1213–1227.
10. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy:the underlying mechanisms and clinical management. Scientifica (Cairo)2013; 2013:857519.
11. Gupta A, De Felice KM, Loftus EV, Jr., Khanna S. Systematic review:colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406–417.
12. Bamias G, Kaltsa G, Siakavellas SI, Gizis M, Margantinis G, Zampeli E, et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis 2012;44:30–36.
13. Bamias G, Goukos D, Laoudi E, Balla IG, Siakavellas SI, Daikos GL, et al. Comparative study of candidate housekeeping genes for quantification of target gene messenger RNA expression by real-time PCR in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2840–2847.
14. Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016;10:395–401.
15. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–2289.
16. Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 2016;14:836–842.
17. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D. Refractory colitis following anti-CTLA4 antibody therapy:analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010;55:1396–1405.
18. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7:827–851.
19. Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res 2006;34:229–242.
20. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010;115:335–343.
21. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015;3:39.
22. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295–302.
23. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271–275.
24. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, et al. Alpha-CTLA-4 mAb-associated panenteritis:a histologic and immunohistochemical analysis. Am J Surg Pathol 2008;32:1130–1137.
25. Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006;177:4376–4383.
26. Marelli-Berg FM, Okkenhaug K, Mirenda V. A two-signal model for T cell trafficking. Trends Immunol 2007;28:267–273.
27. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012;35:89–97.
28. Groschwitz KR, Hogan SP. Intestinal barrier function:molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3–20, quiz 21–22.
29. Shih DQ, Kwan LY, Chavez V, Cohavy O, Gonsky R, Chang EY, et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009;39:3239–3250.
30. Siakavellas SI, Bamias G. Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3:Important New Factors in Mucosal Homeostasis and Inflammation. Inflamm Bowel Dis 2015;21:2441–2452.
31. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.